Image for Antiviral Discovery for Highly Pathogenic Emerging Viruses

Antiviral Discovery for Highly Pathogenic Emerging Viruses

Part of the RSC Drug Discovery series
See all formats and editions

New antiviral drugs are urgently needed. Recent outbreaks caused by viruses with great epidemiological impact such as Zika, or extraordinary virulence such as Ebola, Nipah, Lassa, Crimean-Congo haemorrhagic fever highlight the current lack of clinically proven vaccines and treatments for these potentially catastrophic agents. Antiviral Discovery for Highly Pathogenic Emerging Viruses comprehensively outlines the state of the art in antiviral drug discovery including identification of targets, screening strategies and the current pipeline of antiviral candidates including regulatory issues. The book also addresses the challenges faced in proceeding from pre-clinical studies to animal models and clinical trials with these highly pathogenic agents.

Ideal for drug discovery scientists and medicinal chemists with an interest in antiviral drug discovery and development, this book provides a complete overview of the latest progress in the field, recent advances and the challenges that remain in developing these highly pathogenic agents. Illustrated throughout with case studies this book is a valuable resource in this complex and multidisciplinary field.

Read More
Special order line: only available to educational & business accounts. Sign In
£159.00
Product Details
Royal Society of Chemistry
1839160535 / 9781839160530
eBook (EPUB)
26/11/2021
England
English
1 pages
Copy: 20%; print: 20%
Description based on CIP data; resource not viewed.